Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vir Biotechnology Inc (VIR)

Vir Biotechnology Inc (VIR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,562,509
  • Shares Outstanding, K 127,054
  • Annual Sales, $ 8,090 K
  • Annual Income, $ -174,680 K
  • 60-Month Beta N/A
  • Price/Sales 506.90
  • Price/Cash Flow N/A
  • Price/Book 6.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.55
  • Number of Estimates 4
  • High Estimate -0.23
  • Low Estimate -0.77
  • Prior Year -4.60
  • Growth Rate Est. (year over year) +88.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.16 +33.20%
on 09/10/20
44.00 -17.80%
on 08/31/20
-5.47 (-13.14%)
since 08/28/20
3-Month
27.16 +33.20%
on 09/10/20
55.00 -34.24%
on 08/12/20
-2.66 (-6.85%)
since 06/26/20

Most Recent Stories

More News
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib

The Brazilian Health Regulatory Agency okays RedHill's (RDHL) to conduct a phase II/III study on opaganib for treating patients with severe COVID-19 infection and pneumonia. Stock up.

REGN : 571.92 (-0.37%)
LLY : 148.10 (-1.44%)
RDHL : 9.98 (-1.09%)
VIR : 36.17 (+0.72%)
The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX

The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX

MRNA : 70.55 (+1.55%)
NVAX : 111.18 (-2.10%)
VIR : 36.17 (+0.72%)
BNTX : 66.50 (-0.28%)
4 Biotechs That Have More Than Doubled Thanks to Coronavirus

Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.

JNJ : 147.11 (+1.00%)
PFE : 36.39 (+0.94%)
MRNA : 70.55 (+1.55%)
GSK : 37.86 (+0.16%)
NVAX : 111.18 (-2.10%)
VIR : 36.17 (+0.72%)
BNTX : 66.50 (-0.28%)
Sanofi/Glaxo to Supply 300M Coronavirus Vaccine Doses in EU

Sanofi (SNY) recombinant protein-based technology is being combined with Glaxo's (GSK) pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.

SNY : 51.00 (+0.43%)
GSK : 37.86 (+0.16%)
TBIO : 13.19 (+0.46%)
VIR : 36.17 (+0.72%)
Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody

Sorrento (SRNE) receives an FDA clearance to begin a phase I study on STI-1499 (COVI-GUARD) for treating hospitalized COVID-19 patients. Shares rise.

REGN : 571.92 (-0.37%)
LLY : 148.10 (-1.44%)
SRNE : 10.15 (+5.35%)
VIR : 36.17 (+0.72%)
Lilly's Coronavirus Antibody Shows Positive Effect in Phase II

Lilly (LLY) is developing two coronavirus neutralizing antibody candidates as potential treatment for hospitalized COVID-19 patients. Treatment with one antibody candidate reduces hospitalization rate....

GILD : 62.85 (+0.96%)
INCY : 90.36 (+4.40%)
LLY : 148.10 (-1.44%)
VIR : 36.17 (+0.72%)
What Are The Best Biotech Stocks To Watch Before Friday? 3 To Know

Are These Biotech Stocks Worth The Attention Now?

SRNE : 10.15 (+5.35%)
VIR : 36.17 (+0.72%)
INO : 12.14 (-28.34%)
MRNA : 70.55 (+1.55%)
NVAX : 111.18 (-2.10%)
Lilly's Olumiant Meets Primary Endpoint in Coronavirus Study

Eli Lilly (LLY) releases positive initial data from a phase III study evaluating Olumiant (baricitinib) in combination with Gilead's remdesivir for hospitalized patients with COVID-19.

REGN : 571.92 (-0.37%)
INCY : 90.36 (+4.40%)
LLY : 148.10 (-1.44%)
VIR : 36.17 (+0.72%)
Glaxo/Vir Biotech Begin Clinical Study on Coronavirus Therapy

Glaxo (GSK) and Vir Biotechnology have a collaboration to develop antibody therapies for treating COVID-19.

AZN : 54.75 (-1.37%)
GILD : 62.85 (+0.96%)
GSK : 37.86 (+0.16%)
VIR : 36.17 (+0.72%)
Testing is in High Demand as Spread of Infection Remains

, /PRNewswire/ -- As the pandemic continues to spread throughout the U.S., the need for testing is on the rise. But many states and regions are experiencing a shortage of tests, which is a serious obstacle...

TOMDF : 0.0830 (-1.19%)
MRNA : 70.55 (+1.55%)
VIR : 36.17 (+0.72%)
AZN : 54.75 (-1.37%)
NVAX : 111.18 (-2.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade VIR with:

Business Summary

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus...

See More

Key Turning Points

2nd Resistance Point 38.08
1st Resistance Point 37.12
Last Price 36.17
1st Support Level 34.96
2nd Support Level 33.76

See More

52-Week High 75.00
Fibonacci 61.8% 50.80
Fibonacci 50% 43.33
Last Price 36.17
Fibonacci 38.2% 35.85
52-Week Low 11.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar